• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在意大利的一家中级呼吸重症监护病房,对 COVID-19 患者进行更熟练的临床管理改变了死亡率。

More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy.

机构信息

Department of Basic Medical Science, Institute of Respiratory Disease, Neuroscience, and Sense Organs, University of Bari "Aldo Moro", Bari, Italy.

General Direction, Policlinico Hospital, Bari, Italy.

出版信息

Respir Res. 2021 Jan 15;22(1):16. doi: 10.1186/s12931-021-01613-2.

DOI:10.1186/s12931-021-01613-2
PMID:33451327
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7809547/
Abstract

BACKGROUND

Some studies investigated epidemiological and clinical features of laboratory-confirmed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the virus causing coronavirus disease 2019 (COVID-19), but limited attention has been paid to the follow-up of hospitalized patients on the basis of clinical setting and the expertise of clinical management.

METHODS

In the present single-centered, retrospective, observational study, we reported findings from 87 consecutive laboratory-confirmed COVID-19 patients with moderate-to-severe acute respiratory syndrome hospitalized in an intermediate Respiratory Intensive Care Unit (RICU), subdividing the patients in two groups according to the admission date (before and after March 29, 2020).

RESULTS

With improved skills in the clinical management of COVID-19, we observed a significant lower mortality in the T2 group compared with the T1 group and a significantly difference in terms of mortality among the patients transferred in Intensive Care Unit (ICU) from our intermediate RICU (100% in T1 group vs. 33.3% in T2 group). The average length of stay in intermediate RICU of ICU-transferred patients who survived in T1 and T2 was significantly longer than those who died (who died 3.3 ± 2.8 days vs. who survived 6.4 ± 3.3 days).

T CONCLUSIONS

The present findings suggested that an intermediate level of hospital care may have the potential to modify survival in COVID-19 patients, particularly in the present phase of a more skilled clinical management of the pandemic.

摘要

背景

一些研究调查了实验室确诊的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)患者的流行病学和临床特征,该病毒引起 2019 年冠状病毒病(COVID-19),但对根据临床环境和临床管理专业知识对住院患者进行随访的关注有限。

方法

在本单中心、回顾性、观察性研究中,我们报告了在中间呼吸重症监护病房(RICU)住院的 87 例实验室确诊的 COVID-19 中度至重度急性呼吸综合征患者的发现,根据入院日期(2020 年 3 月 29 日之前和之后)将患者分为两组。

结果

随着 COVID-19 临床管理技能的提高,我们观察到 T2 组的死亡率明显低于 T1 组,并且在从中等 RICU 转入重症监护病房(ICU)的患者中死亡率存在显著差异(T1 组为 100%,T2 组为 33.3%)。在 T1 和 T2 中幸存的从中等 RICU 转入 ICU 的患者的平均住院时间明显长于死亡患者(死亡患者为 3.3±2.8 天,存活患者为 6.4±3.3 天)。

结论

本研究结果表明,中间水平的医院治疗可能有潜力改变 COVID-19 患者的生存,特别是在当前对大流行的临床管理技能更高的阶段。

相似文献

1
More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy.在意大利的一家中级呼吸重症监护病房,对 COVID-19 患者进行更熟练的临床管理改变了死亡率。
Respir Res. 2021 Jan 15;22(1):16. doi: 10.1186/s12931-021-01613-2.
2
Bilevel and continuous positive airway pressure and factors linked to all-cause mortality in COVID-19 patients in an intermediate respiratory intensive care unit in Italy.意大利一家中级呼吸重症监护病房中 COVID-19 患者的双水平和持续气道正压通气与全因死亡率的相关因素。
Expert Rev Respir Med. 2021 Jun;15(6):853-857. doi: 10.1080/17476348.2021.1866546. Epub 2020 Dec 23.
3
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.意大利伦巴第地区 1591 名 ICU 收治的 SARS-CoV-2 感染患者的基线特征和结局。
JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394.
4
Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.重症监护治疗新型冠状病毒 SARS-CoV-2 感染患者:意大利克雷马医院的经验。
Am J Emerg Med. 2021 Jul;45:156-161. doi: 10.1016/j.ajem.2020.08.005. Epub 2020 Aug 16.
5
Risk factors for transfer from Respiratory Intermediate Care Unit to Intensive Care Unit in COVID-19.COVID-19 患者从呼吸重症监护病房转入重症监护病房的危险因素。
Respir Investig. 2021 Sep;59(5):602-607. doi: 10.1016/j.resinv.2021.05.002. Epub 2021 Jun 1.
6
Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.意大利伦巴第地区重症监护病房中 COVID-19 患者死亡的相关危险因素。
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355. doi: 10.1001/jamainternmed.2020.3539.
7
Characteristics and outcomes of patients with COVID-19 admitted to hospital and intensive care in the first phase of the pandemic in Canada: a national cohort study.加拿大疫情第一阶段住院和重症监护的 COVID-19 患者的特征和结局:一项全国性队列研究。
CMAJ Open. 2021 Mar 8;9(1):E181-E188. doi: 10.9778/cmajo.20200250. Print 2021 Jan-Mar.
8
Characteristics and outcomes of critically ill patients with covid-19 in Sakarya, Turkey: a single centre cohort study.土耳其萨卡里亚市新冠肺炎危重症患者的特征和结局:一项单中心队列研究。
Turk J Med Sci. 2021 Apr 30;51(2):440-447. doi: 10.3906/sag-2005-57.
9
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
10
Coronavirus Disease 2019 ICU Patients Have Higher-Than-Expected Acute Physiology and Chronic Health Evaluation-Adjusted Mortality and Length of Stay Than Viral Pneumonia ICU Patients.COVID-19 重症监护病房患者的急性生理学与慢性健康状况评估调整死亡率和住院时间高于病毒性肺炎重症监护病房患者。
Crit Care Med. 2021 Jul 1;49(7):e701-e706. doi: 10.1097/CCM.0000000000005012.

引用本文的文献

1
What Is the Place of Intermediate Care Unit in Patients with COVID-19? A Single Center Experience.《COVID-19 患者的中级护理单元的地位如何?一项单中心经验》。
Int J Clin Pract. 2023 Apr 20;2023:8545431. doi: 10.1155/2023/8545431. eCollection 2023.
2
Outcomes of COVID-19 Patients Admitted to the Intermediate Respiratory Care Unit: Non-Invasive Respiratory Therapy in a Sequential Protocol.COVID-19 患者入住中级呼吸治疗病房的结局:序贯方案中的无创呼吸治疗。
Int J Environ Res Public Health. 2022 Aug 29;19(17):10772. doi: 10.3390/ijerph191710772.
3
Revealing the toxicity of lopinavir- and ritonavir-containing water and wastewater treated by photo-induced processes to Danio rerio and Allivibrio fischeri.揭示光诱导处理含洛匹那韦和利托那韦的水和废水对斑马鱼和发光菌的毒性。
Sci Total Environ. 2022 Jun 10;824:153967. doi: 10.1016/j.scitotenv.2022.153967. Epub 2022 Feb 17.
4
Factors influencing nurses' behavioral intention toward caring for COVID-19 patients on mechanical ventilation: A cross-sectional study.影响护士对机械通气新冠肺炎患者护理行为意向的因素:一项横断面研究。
PLoS One. 2021 Nov 5;16(11):e0259658. doi: 10.1371/journal.pone.0259658. eCollection 2021.
5
Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients.吸烟、COPD 及合并症对 COVID-19 患者死亡率的影响。
Sci Rep. 2021 Sep 28;11(1):19251. doi: 10.1038/s41598-021-98749-4.
6
Imaging Evaluation of Pulmonary and Non-Ischaemic Cardiovascular Manifestations of COVID-19.新型冠状病毒肺炎肺部及非缺血性心血管表现的影像学评估
Diagnostics (Basel). 2021 Jul 15;11(7):1271. doi: 10.3390/diagnostics11071271.
7
COVID-19 clinical phenotypes and short-term outcomes: differences between the first and the second wave of pandemic in Italy.COVID-19 临床表型和短期结局:意大利疫情第一波和第二波的差异。
Expert Rev Respir Med. 2021 Dec;15(12):1619-1625. doi: 10.1080/17476348.2021.1960824. Epub 2021 Aug 18.

本文引用的文献

1
Bilevel and continuous positive airway pressure and factors linked to all-cause mortality in COVID-19 patients in an intermediate respiratory intensive care unit in Italy.意大利一家中级呼吸重症监护病房中 COVID-19 患者的双水平和持续气道正压通气与全因死亡率的相关因素。
Expert Rev Respir Med. 2021 Jun;15(6):853-857. doi: 10.1080/17476348.2021.1866546. Epub 2020 Dec 23.
2
The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis.羟氯喹治疗 COVID-19 患者的结局:系统评价和荟萃分析。
Can Respir J. 2020 Oct 13;2020:4312519. doi: 10.1155/2020/4312519. eCollection 2020.
3
A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects.多尺度吸收和传递模型用于羟氯喹的口服给药:药代动力学建模和肠道浓度预测,以评估健康受试者的毒性和药物诱导损伤。
Int J Numer Method Biomed Eng. 2020 Dec;36(12):e3403. doi: 10.1002/cnm.3403. Epub 2020 Oct 15.
4
After 62 years of regulating immunity, dexamethasone meets COVID-19.地塞米松调控免疫 62 年后迎击 COVID-19。
Nat Rev Immunol. 2020 Oct;20(10):587-588. doi: 10.1038/s41577-020-00421-x.
5
Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis.新型冠状病毒肺炎感染患者的重症危险因素及治疗效果:一项系统评价、荟萃分析和Meta回归分析
Clin Infect Dis. 2020 Nov 19;71(16):2199-2206. doi: 10.1093/cid/ciaa576.
6
Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study.韩国大邱市 98 例住院 SARS-CoV-2 感染患者的临床特征和结局:一项简要描述性研究。
Yonsei Med J. 2020 May;61(5):431-437. doi: 10.3349/ymj.2020.61.5.431.
7
COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal.新冠病毒疾病在自然状态和免疫抑制状态下:一项临床治疗分期建议。
J Heart Lung Transplant. 2020 May;39(5):405-407. doi: 10.1016/j.healun.2020.03.012. Epub 2020 Mar 20.
8
The many faces of the anti-COVID immune response.抗新冠病毒免疫反应的多面性。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200678.
9
Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy.意大利布雷西亚严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染危重症患者的临床表现和初步治疗。
J Crit Care. 2020 Aug;58:29-33. doi: 10.1016/j.jcrc.2020.04.004. Epub 2020 Apr 14.
10
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations.2019 冠状病毒病(COVID-19)的重症监护管理:挑战与建议。
Lancet Respir Med. 2020 May;8(5):506-517. doi: 10.1016/S2213-2600(20)30161-2. Epub 2020 Apr 6.